Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACKR3 | P25106 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | WNT1 | P04628 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TAF1 | P21675 | 1/20 | 0.45 |
| ▸ | CECR2 | Q9BXF3 | 1/20 | 0.45 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3343302 | 0.87 | HPGD (0.55) | HRH3KMT2AUSP30ALDH1A1NPC1 | |
| SCHEMBL18010687 | 0.85 | ACKR3 (0.55) | ACKR3HRH3KMT2ACDK1CDK2 | |
| SCHEMBL1781864 | 0.85 | ACKR3 (0.55) | ACKR3HRH3KMT2ACDK1CDK2 | |
| SCHEMBL31495198 | 0.85 | KMT2A (0.52) | KMT2AUSP30ALDH1A1NPC1RAB9A | |
| SCHEMBL16935503 | 0.85 | RAB9A (0.51) | KMT2AUSP30ALDH1A1NPC1LMNA | |
| SCHEMBL3343582 | 0.85 | NPC1 (0.55) | KMT2AUSP30ALDH1A1NPC1LMNA | |
| SCHEMBL26170021 | 0.84 | KMT2A (0.51) | ACKR3KMT2ADYRK1ANPC1RAB9A | |
| SCHEMBL506741 | 0.83 | NPC1 (0.57) | KMT2AALDH1A1NPC1LMNAGAA | |
| SCHEMBL27261779 | 0.83 | KMT2A (0.50) | ACKR3KMT2ATAF1CECR2BRD9 | |
| SCHEMBL3544000 | 0.82 | ACKR3 (0.45) | ACKR3KMT2AUSP30WNT1DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| CN-101115752-A | 4- (4- (imidazol-4-yl) pyrimidin-2-ylamino) benzamides as cdk inhibitors | ASTRAZENECA AB (SE) | 2008-01-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099160-A1 | 4-(4-(Imidazol-4-Yl) Pyrimidin-2-Ylamino) Benzamides as CDK Inhibitors | CCNI, CDK4, CDK3 | ACKR3 4525/4885HRH3 550/4885KMT2A 329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.